Top Markets
#1 Pleasing Gold Pleasing Gold +676.53%
#2 Islamic Coin Islamic Coin +154.21%
#3 PulseChain PulseChain +56.20%
#4 BOOK OF MEME BOOK OF MEME +41.35%
#5 DogBull DogBull +37.99%
#6 Collect on Fanable Collect on Fanable +22.96%
#7 Neiro Neiro +17.90%
#8 Nockchain Nockchain +17.43%
#9 rsERG rsERG +16.87%
#10 PondCoin PondCoin +16.85%
Coin of the day
Pleasing Gold Pleasing Gold
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
TCR2 Therapeutics Inc. TCR2 Therapeutics Inc.

TCR2 Therapeutics Inc.

TCRR
Classement en actions #27036
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on... TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on developing cutting-edge T cell receptor (TCR) therapies for cancer patients. The company's lead investigational treatment, gavo-cel, is a unique mono TCR Fusion Construct T cell (TRuC-T cell) designed to target mesothelin-positive solid tumors. This therapy is currently being evaluated in Phase I/II clinical trials for non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Furthermore, TCR2 Therapeutics has concluded preclinical development for TC-510, another TRuC-T cell specifically engineered to target mesothelin on solid tumors. They are also advancing TC-520, a CD70-targeting TRuC-T cell designed with fratricide resistance for treating renal cell carcinoma. Founded in 2015, the company, formerly known as TCR2, Inc. until its name change in November 2016, is headquartered in Cambridge, Massachusetts.
Prix de l'action
$1.48
Dernière synchronisation: 2023-05-31
Capitalisation boursière
$35.54M
Changement (1 jour)
-5.73%
Changement (1 an)
0.00%
Pays
US
Échange TCR2 Therapeutics Inc. (TCRR)

Catégorie

Healthcare
Bénéfices pour TCR2 Therapeutics Inc. (TCRR)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de TCR2 Therapeutics Inc., les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour TCR2 Therapeutics Inc. de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH